Sareum Holdings PLC Change of Adviser (2470J)
16 August 2019 - 4:00PM
UK Regulatory
TIDMSAR
RNS Number : 2470J
Sareum Holdings PLC
16 August 2019
(AIM:SAR) 16 August 2019
Sareum Holdings PLC
("Sareum" or the "Company")
Appointment of Nominated Adviser
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, is pleased to announce the appointment
of Strand Hanson Limited as Nominated & Financial Adviser to
the Company with immediate effect.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information, contact:
Sareum Holdings PLC
Tim Mitchell +44 (0) 12 2349 7700
Strand Hanson Limited (Nominated & Financial Adviser) +44 (0) 20 7409 3494
Richard Tulloch
James Dance
Eric Allan
Hybridan LLP (Broker) +44 (0) 20 3764 2341
Claire Noyce
John Beresford-Peirse
Citigate Dewe Rogerson (Media enquiries) +44 (0) 20 7638 9571
Shabnam Bashir
Mark Swallow
David Dible
Notes to editor:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting multiple
advanced cancers. The key role of Chk1 in cancer cell replication
and DNA damage repair suggests that SRA737 may have broad
application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research, London, UK in collaboration with
Sareum, and with funding from Cancer Research UK. SRA737 was
licensed to Sierra Oncology for up to $328.5 million plus royalties
by Sareum's co-investment partner, CRT Pioneer Fund. Sareum is
eligible to receive up to $88 million in milestone payments, plus
sales royalties as SRA737 advances.
Notable highlights from the Phase 1/2 preliminary results
reported by Sierra at ASCO (June 2019) were:
SRA737 + low dose gemcitabine (LDG) combination
-- Striking anti-tumour activity was observed in patients with
anogenital cancer, including examples where metastatic disease was
cleared from liver and lung.
-- Tumour size decreased by more than a third in 30% of the
evaluable anogenital cancer patients and a further 30% had durable
stable disease.
-- Sierra outlined a potential route to market for SRA737+LDG in
anogenital cancer via a registration-intent Phase 2 trial.
SAR737 monotherapy
High-grade serous ovarian cancers (HGSOC) appeared to be the
most sensitive tumour to SRA737, with the disease being controlled
(stable disease) in 54% of evaluable patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have
roles in pro-inflammatory responses in autoimmune diseases (e.g.
psoriasis, rheumatoid arthritis, inflammatory bowel diseases and
lupus) and tumour cell proliferation in certain cancers (e.g.
T-cell acute lymphoblastic leukaemia and some solid tumours). The
Company is targeting first human clinical trials in each indication
in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPBLGDIRBBBGCU
(END) Dow Jones Newswires
August 16, 2019 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024